Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Alliance Grants

Dalhousie University

$25,000.00

Systematic development of degradable itaconate polymer microparticles to achieve intracellular small molecule immunomodulation

FY 2024-25

Summary
Recent advances in immunology highlight the power of metabolites, small molecules that fuel our cellular energy production systems, as functional regulators of inflammation in our bodies' homeostasis. Our group has developed degradable biomaterials that utilize one of these molecules, itaconate, as a key building block for the polymer to regulate immune cells in a controlled and timely manner. To specifically target and improve efficacy of these material technologies, we formulated these materials into micron-sized particles to regulate cells from the inside out. In this project, we will expand on this proof-of-concept work through systematic development of a library of materials that can release itaconate in a predicable manner, focused on release timelines relevant to delivery inside the cell (<24hr). Establishment of an international collaboration will allow us to characterize the regulatory capacity these materials have with dendritic cells, an important immune cell subset in various types of inflammation. Our expertise in degradable biomaterial development, coupled with collaborative knowledge of mechanisms of dendritic cell inflammation, will achieve a direct correlation between material development and immune-regulatory properties. To establish a robust international collaboration, this one-year project will place an emphasis on building robust scientific relationships between HQP focused on a fundamental understanding of material properties to optimize new biomaterial technologies. Success and validation of this approach would establish a platform technology of interest to an ever-growing biomaterial-based drug delivery industry, and further strengthen Canada's expertise in this sector.
Program
Alliance Grants
Location
Nova Scotia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
597098-2024
Name nom
Davenport Huyer, Locke LS
Department département
Applied Oral Sciences,
Organization id
79
Institution établissement
Dalhousie University
Province en
Nova Scotia
Province fr
Nouvelle-Écosse
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
25000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Systematic development of degradable itaconate polymer microparticles to achieve intracellular small molecule immunomodulation
Keywords
biomaterials; degradable polyester; dendritic cells; immunometabolism; immunomodulation; microparticles; polymer synthesis
Application summary
Recent advances in immunology highlight the power of metabolites, small molecules that fuel our cellular energy production systems, as functional regulators of inflammation in our bodies' homeostasis. Our group has developed degradable biomaterials that utilize one of these molecules, itaconate, as a key building block for the polymer to regulate immune cells in a controlled and timely manner. To specifically target and improve efficacy of these material technologies, we formulated these materials into micron-sized particles to regulate cells from the inside out. In this project, we will expand on this proof-of-concept work through systematic development of a library of materials that can release itaconate in a predicable manner, focused on release timelines relevant to delivery inside the cell (<24hr). Establishment of an international collaboration will allow us to characterize the regulatory capacity these materials have with dendritic cells, an important immune cell subset in various types of inflammation. Our expertise in degradable biomaterial development, coupled with collaborative knowledge of mechanisms of dendritic cell inflammation, will achieve a direct correlation between material development and immune-regulatory properties. To establish a robust international collaboration, this one-year project will place an emphasis on building robust scientific relationships between HQP focused on a fundamental understanding of material properties to optimize new biomaterial technologies. Success and validation of this approach would establish a platform technology of interest to an ever-growing biomaterial-based drug delivery industry, and further strengthen Canada's expertise in this sector.